
Nanordica Medical
Develops first-in-class antibacterial wound care products.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
* | €1.8m | Seed | |
Total Funding | 000k |
Related Content
The only company in the world developing first-in-class wound care products based on synergistic nanoparticles that manage infection and support wound healing simultaneously, leading to faster wound closure. Nanordica Medical recently completed a randomized active-controlled clinical study on patients with severe wounds (diabetic foot ulcers) that showed that their solution healed wounds 2 times faster than the standard of care, including hard-to-heal wounds. In 2023, their solution was awarded a highly competitive EIC Accelerator grant that supports top innovators in the EU.
Keywords: Healthcare Devices, Services, Supplies, Antibacterial Devices, Antibacterial Product, Antibacterial Products, Healthcare Hardware, Healthcare Product, Medical Equipment, Medical Equipment Retail.